RxSight (RXST) EBITDA (2020 - 2026)

RxSight's EBITDA history runs 7 years deep, the most recent figure standing at -$17.8 million for Q1 2026.

• Quarterly EBITDA fell 67.03% year-over-year to -$17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$55.3 million (down 50.07% YoY) and the FY2025 annual result came in at -$48.2 million, down 30.62% from the prior year.
• EBITDA was -$17.8 million for Q1 2026 at RxSight, down from -$11.3 million in the prior quarter.
• Across five years, EBITDA topped out at $16.0 million in Q3 2022 and bottomed at -$89.3 million in Q4 2023.
• A 5-year average of -$10.5 million and a median of -$10.7 million in 2025 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA surged 213.86% — and 2023, when it sank 495.73%.
• RxSight's EBITDA stood at -$15.0 million in 2022, then sank by 495.73% to -$89.3 million in 2023, then soared by 90.29% to -$8.7 million in 2024, then sank by 30.33% to -$11.3 million in 2025, then plunged by 57.78% to -$17.8 million in 2026.
• Business Quant data shows RXST's EBITDA at -$17.8 million in Q1 2026, -$11.3 million in Q4 2025, and -$12.2 million in Q3 2025.